Payment overview · 2025
General Payments
$709.66
37 reported records · 16 companies
Healthcare provider profile · identity verified
Charles Thornton, NURSE PRACTITIONER
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CULLMAN, AL · NPI 1447631692
Verified facts
What the public records show
CMS Open Payments records show Charles Thornton, NURSE PRACTITIONER received $709.66 in general payments during 2025 across 37 reported records.
ABBVIE INC. accounted for 25.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $183.97 | 25.9% | 11 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $115.30 | 16.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.42 | 9.9% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.22 | 8.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.16 | 7.1% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.40 | 4.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.48 | 3.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.42 | 3.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.47 | 3.3% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $21.96 | 3.1% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.30 | 2.9% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.42 | 2.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.84 | 2.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.82 | 2.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.50 | 2.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.98 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $709.66 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $115.30 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $112.95 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $71.02 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $71.02 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.42 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.67 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.40 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.47 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.30 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $19.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $16.82 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 30 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 69 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 65 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 63 | 34 |
| Atorvastatin Calcium | Atorvastatin Calcium | 59 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 48 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 30 |
| Prednisone | Prednisone | 46 | 38 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 40 |
| Furosemide | Furosemide | 42 | 26 |
| Omeprazole | Omeprazole | 34 | 21 |
| Trazodone Hcl | Trazodone Hcl | 34 | 16 |
| Potassium Chloride | Potassium Chloride | 32 | 15 |
| Metformin Hcl | Metformin Hcl | 31 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 19 |
| Eliquis | Apixaban | 30 | 11 |
| Buspirone Hcl | Buspirone Hcl | 29 | 13 |
| Montelukast Sodium | Montelukast Sodium | 29 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | 12 |
| Rybelsus | Semaglutide | 28 | suppressed |
| Famotidine | Famotidine | 26 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 12 |
| Cefdinir | Cefdinir | 25 | 25 |
| Lisinopril | Lisinopril | 25 | 14 |
| Allopurinol | Allopurinol | 24 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 24 | 12 |
| Meloxicam | Meloxicam | 23 | 12 |
| Carvedilol | Carvedilol | 22 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | 11 |
| Ozempic | Semaglutide | 17 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | 12 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $709.66 · 37 records | ABBVIE INC. | Dexcom G6 Transmitter, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, INSPIRE, JATENZO, Kerendia, Korlym, LEQEMBI, MINIMED 780G, NURTEC ODT, Ozempic, QULIPTA, RECORLEV, REXULTI, Rybelsus, TRINTELLIX, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error